Medios AG

  • ISIN: DE000A1MMCC8
  • Land: Deutschland

Nachricht vom 26.10.2021 | 13:00

Medios AG: Sales more than doubled in the first nine months of 2021 - disproportionate increase in earnings

DGAP-News: Medios AG / Key word(s): Preliminary Results/9 Month figures
26.10.2021 / 13:00
The issuer is solely responsible for the content of this announcement.

Press Release

Medios AG: Sales more than doubled in the first nine months of 2021 - disproportionate increase in earnings

Berlin, October 26, 2021 - Medios AG ("Medios"), the leading provider of Specialty Pharma Solutions in Germany, grew strongly in the first nine months of the 2021 financial year. Based on preliminary figures, group sales in the period from January to September increased by 118.3% to €988.8 million compared to the same period of the previous year (€452.9 million). EBITDA pre1 rose to €28.1 million (previous year €10.2 million), an increase of 174.7%. EBT pre1 climbed by 202.8% to €24.3 million (previous year €8.0 million).

Matthias Gaertner, CEO of Medios AG: "In the first nine months, we have increased our sales to almost one billion euros. We are confident of continuing our growth trend: in particular, through further acquisitions focusing on the areas of manufacturing and digitization."

Falk Neukirch, CFO of Medios AG: "The third quarter, like the previous quarter and the corresponding quarter of the previous year, was very good and in terms of sales and EBITDA pre the best in the Company's history."

Outlook for 2021 confirmed
Medios expects strong growth in the 2021 financial year despite the continued challenging market environment and confirms its sales guidance. Accordingly, the Company continues to expect group sales of €1.2 to 1.3 billion (+ 92 to 107%). Medios also confirms its earnings forecast. Accordingly, the Company continues to expect EBITDA pre1 of €38 to 39 million (+ 152 to 159%) and EBT pre1 of €31 to 32 million (+ 158 to 166%).

The final financial figures for the first nine months of 2021 will be published on the Investor Relations website with the next quarterly statement on November 9, 2021.

1 EBITDA is defined as net earnings before interest, income taxes, depreciation and amortization. EBT is defined as net earnings before income taxes. EBITDA pre and EBT pre are each adjusted for extraordinary expenses for stock options, M&A activities and amortization of the customer base.


About Medios AG
Medios AG is the leading provider of Specialty Pharma solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.

Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).

Claudia Nickolaus
Head of Investor & Public Relations
Medios AG
Heidestraße 9 | 10557 Berlin| Germany
P +49 30 232 566 800

Nikolaus Hammerschmidt
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg| Germany
P +49 40 609 186 18

This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.

26.10.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021